Filing Overview
ORIC Pharmaceuticals, Inc. filed a Form 8-K dated June 9, 2020, with the report signed June 10, 2020. The filing concerns the appointment of a new director and does not report quarterly or annual operating results.
Material Corporate Event
On June 9, 2020, the Board appointed Dr. Lori Kunkel as a Class I director, with a term expiring at the 2021 annual meeting of stockholders.
- The filing states that there were no arrangements or understandings relating to her selection.
- No related-party transaction requiring disclosure under Item 404(a) of Regulation S-K was reported.
- Dr. Kunkel executed the Company’s standard indemnification agreement.
Compensation
- Annual cash retainer of $35,000 under the non-employee director compensation policy.
- Option grant for 28,515 shares of common stock.
- The option vests at 1/36 per month, subject to continued service, and fully accelerates upon a qualifying change in control.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, balance-sheet figures, or other operating metrics.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, business outlook commentary, new risk disclosures, contingencies, or unusual financial items.
Investor Verification Points
- Confirm Dr. Kunkel’s appointment and term through the Company’s subsequent proxy or other corporate filings.
- Review the Company’s director compensation policy and equity award terms for the applicable vesting and change-in-control provisions.
- Review subsequent filings for any changes to board composition, director compensation, or the status of the option grant.
- Consult separate periodic filings for the Company’s financial condition, cash runway, operating results, and financing needs.